$CSU Constellation Software just reported Q3, and it's a better quarter than the headline makes it look.

Thread by The Fox@Alpha_Fox11 · Nov 6, 2026 · 17 posts · 1,215 words · 8 min read

$CSU Constellation Software just reported Q3, and it's a better quarter than the headline makes it look. Revenue $3.51B, up 19%. Maintenance organic growth back to 4% after FX, double last quarter. The core business outside US healthcare grew recurring revenue 5%. Altera's bleeding slowed sharply. And they've spent 2.5x more on acquisitions this year than last. The one ugly number is free cash flow to shareholders, down 16%. That one has a story behind it too. Full breakdown below.
1/17View on X
Start with the top line. Revenue was $3.51B, up 19% from $2.95B. Only about 2 points of that was organic. The rest came from the acquisitions Constellation keeps stacking, now over 1,600 businesses across more than 100 verticals. 77% of revenue is maintenance and recurring, $2.7B a quarter that customers pay year after year. Trailing 12 month revenue is now $13.2B.
2/17View on X
Organic growth is the number everyone watches, and this quarter it moved the right way. Maintenance and recurring revenue grew 4% organically after FX, up from 2% last quarter, which spooked a lot of people. Total organic growth was 2%, up from 1%. This is the line that tells you whether customers are sticking around. After a year of "AI is going to kill vertical software," the recurring base is still growing.
3/17View on X
Here's the best new disclosure in the report. For the first time, Constellation split out its problem children. Strip out the US healthcare businesses and Altera, and maintenance organic growth was 5% this quarter, up from 4%. That core has grown 5% to 7% every year since 2016 except 2020. US healthcare outside Altera shrank 10%, but management says that's mostly two businesses bought this period with high customer attrition that was known and modeled into the price. Excluding those two, it was down 3%.
4/17View on X
Altera, the hospital software business bought from Allscripts in 2022, has been the biggest drag. Its recurring revenue shrank 19% organically in Q2. This quarter it shrank 8%. Management was unusually direct: most of the decline comes from several large clients leaving in multi year transitions, and they expect that to run its course by the end of 2027. Altera is only $144M of quarterly revenue now, about 4% of the company, so its drag on the whole gets smaller every quarter.
5/17View on X
The AI bear case says new software sales dry up first. You can actually see that here. License revenue fell 17% organically and professional services fell 5%. Those are the one time, project based sales. But maintenance and recurring revenue, 77% of the total, grew 4%. Customers are being careful about new projects. They aren't ripping out the systems they run their business on.
6/17View on X
Now the number the bears will grab: free cash flow available to shareholders was $443M, down 16% from $529M. Context matters. CSU's cash flow is lumpy and seasonal, with Q1 the biggest and Q2 the smallest because of when maintenance contracts renew. Over nine months FCFA2S is $1.52B, up 21%. Trailing 12 months it's $1.94B, or $91.74 a share. Operating cash flow was actually up 5% in Q3.
7/17View on X
So why was Q3 down? Mostly one line. FCFA2S is calculated after deducting the IRGA / TSS revaluation charge, which tracks what Constellation owes the minority holders at Topicus. It rises when Topicus, Asseco and Sygnity shares go up. This quarter the charge was $117M versus $16M a year ago, and $77M of it came from Asseco and Sygnity share prices alone. Add it back and FCFA2S was roughly $560M versus $545M, up about 3%. The drop is mostly a side effect of the family's stocks doing well.
8/17View on X
The capital allocation story is the real headline. Constellation spent $1.91B in cash buying businesses in the first nine months, up from $755M last year, about 2.5x. Q3 alone was $484M versus $281M. And since quarter end they've closed or committed another $673M, in verticals from gaming and mining to local government and insurance. That's more than all the FCFA2S they generated this year. The machine is deploying again.
9/17View on X
Margins held. Expenses were 73% of revenue, the same as a year ago. Staff costs rose 17%, a bit slower than revenue. The pockets to watch are sales and marketing, up 25%, and G&A, up 21%, both running ahead of revenue as newly acquired businesses get folded in. Not a red flag yet, but it's the line I'd watch if organic growth stays in the low single digits.
10/17View on X
The family breakdown tells you where the growth is. Topicus grew recurring revenue 7% organically. Lumine grew 6%. Constellation excluding the two spinouts grew 3%, weighed down by US healthcare and Altera. Topicus and Lumine now do about $800M of quarterly revenue between them, and they're the fastest growers in the group. Owning $CSU gets you a big slice of both. $TOI.V $LMN.V
11/17View on X
All that buying hasn't stretched the balance sheet. Cash is $2.69B and debt is $4.0B, for net debt of $1.31B, up from $1.04B at year end, while they spent nearly $2B on acquisitions. Debt actually fell $132M this year. One caveat: about $1.0B of that cash sits at Topicus, Lumine and other subsidiaries with their own debt, so not all of it is free for the parent to use.
12/17View on X
The stock has had a wild two years. $CSU.TO peaked around C$5,113 in May 2025, then fell more than 50% through the AI disruption scare to C$2,295 in April 2026. It closed today at C$3,527 before results, still 31% below the high but up 54% from the low. Results came out after the close, so Monday is the first real reaction.
13/17View on X
Here's what that did to the multiple. At the 2025 peak you were paying about 49x trailing FCFA2S. At the bottom this spring it was about 20x. Today it's about 27x, roughly US$2,496 a share against $91.74 of trailing FCFA2S. Same company, more cash flow per share than ever, and close to half the multiple.
14/17View on X
So what has to be true from here? If FCFA2S per share compounds 12% a year for five years and the multiple settles at 25x, the stock is worth about US$4,040, roughly 10% a year from here. The bull case, 15% growth and 28x, gets you about 16% a year. The bear case, 8% growth and 20x, is close to flat, about 2% a year. The math says you're being paid for continued execution, not paying up for perfection.
15/17View on X
Bull vs bear. Bull: recurring growth bounced back, the core outside healthcare is growing 5%, Altera's drag is fading, deal spending is up 2.5x, and the balance sheet is fine. You're paying 27x for a compounder the market paid 49x for last year. Bear: total organic growth is still only 2%, license and services are shrinking, US healthcare keeps losing customers, sales and G&A costs are outrunning revenue, and the IRGA charge will keep swinging cash flow around as Topicus rises.
16/17View on X
My take: a quiet quarter for the business and a loud one for capital deployment. The AI fear hasn't shown up where it would matter most, in maintenance revenue. What I'm watching: Monday's 8am call with Mark Miller, any color from the Chief AI Officer they appointed in October, whether core organic growth holds at 5%, Altera's runoff, and how much of that $673M pipeline closes in Q4. $CSU.TO #ConstellationSoftware
17/17View on X

$CSU Constellation Software just reported Q3, and it's a better quarter than the headline makes it look.

Thread by The Fox@Alpha_Fox11 · Nov 6, 2026 · 17 posts · 1,215 words · 8 min read

$CSU Constellation Software just reported Q3, and it's a better quarter than the headline makes it look. Revenue $3.51B, up 19%. Maintenance organic growth back to 4% after FX, double last quarter. The core business outside US healthcare grew recurring revenue 5%. Altera's bleeding slowed sharply. And they've spent 2.5x more on acquisitions this year than last. The one ugly number is free cash flow to shareholders, down 16%. That one has a story behind it too. Full breakdown below.
1/17View on X
Start with the top line. Revenue was $3.51B, up 19% from $2.95B. Only about 2 points of that was organic. The rest came from the acquisitions Constellation keeps stacking, now over 1,600 businesses across more than 100 verticals. 77% of revenue is maintenance and recurring, $2.7B a quarter that customers pay year after year. Trailing 12 month revenue is now $13.2B.
2/17View on X
Organic growth is the number everyone watches, and this quarter it moved the right way. Maintenance and recurring revenue grew 4% organically after FX, up from 2% last quarter, which spooked a lot of people. Total organic growth was 2%, up from 1%. This is the line that tells you whether customers are sticking around. After a year of "AI is going to kill vertical software," the recurring base is still growing.
3/17View on X
Here's the best new disclosure in the report. For the first time, Constellation split out its problem children. Strip out the US healthcare businesses and Altera, and maintenance organic growth was 5% this quarter, up from 4%. That core has grown 5% to 7% every year since 2016 except 2020. US healthcare outside Altera shrank 10%, but management says that's mostly two businesses bought this period with high customer attrition that was known and modeled into the price. Excluding those two, it was down 3%.
4/17View on X
Altera, the hospital software business bought from Allscripts in 2022, has been the biggest drag. Its recurring revenue shrank 19% organically in Q2. This quarter it shrank 8%. Management was unusually direct: most of the decline comes from several large clients leaving in multi year transitions, and they expect that to run its course by the end of 2027. Altera is only $144M of quarterly revenue now, about 4% of the company, so its drag on the whole gets smaller every quarter.
5/17View on X
The AI bear case says new software sales dry up first. You can actually see that here. License revenue fell 17% organically and professional services fell 5%. Those are the one time, project based sales. But maintenance and recurring revenue, 77% of the total, grew 4%. Customers are being careful about new projects. They aren't ripping out the systems they run their business on.
6/17View on X
Now the number the bears will grab: free cash flow available to shareholders was $443M, down 16% from $529M. Context matters. CSU's cash flow is lumpy and seasonal, with Q1 the biggest and Q2 the smallest because of when maintenance contracts renew. Over nine months FCFA2S is $1.52B, up 21%. Trailing 12 months it's $1.94B, or $91.74 a share. Operating cash flow was actually up 5% in Q3.
7/17View on X
So why was Q3 down? Mostly one line. FCFA2S is calculated after deducting the IRGA / TSS revaluation charge, which tracks what Constellation owes the minority holders at Topicus. It rises when Topicus, Asseco and Sygnity shares go up. This quarter the charge was $117M versus $16M a year ago, and $77M of it came from Asseco and Sygnity share prices alone. Add it back and FCFA2S was roughly $560M versus $545M, up about 3%. The drop is mostly a side effect of the family's stocks doing well.
8/17View on X
The capital allocation story is the real headline. Constellation spent $1.91B in cash buying businesses in the first nine months, up from $755M last year, about 2.5x. Q3 alone was $484M versus $281M. And since quarter end they've closed or committed another $673M, in verticals from gaming and mining to local government and insurance. That's more than all the FCFA2S they generated this year. The machine is deploying again.
9/17View on X
Margins held. Expenses were 73% of revenue, the same as a year ago. Staff costs rose 17%, a bit slower than revenue. The pockets to watch are sales and marketing, up 25%, and G&A, up 21%, both running ahead of revenue as newly acquired businesses get folded in. Not a red flag yet, but it's the line I'd watch if organic growth stays in the low single digits.
10/17View on X
The family breakdown tells you where the growth is. Topicus grew recurring revenue 7% organically. Lumine grew 6%. Constellation excluding the two spinouts grew 3%, weighed down by US healthcare and Altera. Topicus and Lumine now do about $800M of quarterly revenue between them, and they're the fastest growers in the group. Owning $CSU gets you a big slice of both. $TOI.V $LMN.V
11/17View on X
All that buying hasn't stretched the balance sheet. Cash is $2.69B and debt is $4.0B, for net debt of $1.31B, up from $1.04B at year end, while they spent nearly $2B on acquisitions. Debt actually fell $132M this year. One caveat: about $1.0B of that cash sits at Topicus, Lumine and other subsidiaries with their own debt, so not all of it is free for the parent to use.
12/17View on X
The stock has had a wild two years. $CSU.TO peaked around C$5,113 in May 2025, then fell more than 50% through the AI disruption scare to C$2,295 in April 2026. It closed today at C$3,527 before results, still 31% below the high but up 54% from the low. Results came out after the close, so Monday is the first real reaction.
13/17View on X
Here's what that did to the multiple. At the 2025 peak you were paying about 49x trailing FCFA2S. At the bottom this spring it was about 20x. Today it's about 27x, roughly US$2,496 a share against $91.74 of trailing FCFA2S. Same company, more cash flow per share than ever, and close to half the multiple.
14/17View on X
So what has to be true from here? If FCFA2S per share compounds 12% a year for five years and the multiple settles at 25x, the stock is worth about US$4,040, roughly 10% a year from here. The bull case, 15% growth and 28x, gets you about 16% a year. The bear case, 8% growth and 20x, is close to flat, about 2% a year. The math says you're being paid for continued execution, not paying up for perfection.
15/17View on X
Bull vs bear. Bull: recurring growth bounced back, the core outside healthcare is growing 5%, Altera's drag is fading, deal spending is up 2.5x, and the balance sheet is fine. You're paying 27x for a compounder the market paid 49x for last year. Bear: total organic growth is still only 2%, license and services are shrinking, US healthcare keeps losing customers, sales and G&A costs are outrunning revenue, and the IRGA charge will keep swinging cash flow around as Topicus rises.
16/17View on X
My take: a quiet quarter for the business and a loud one for capital deployment. The AI fear hasn't shown up where it would matter most, in maintenance revenue. What I'm watching: Monday's 8am call with Mark Miller, any color from the Chief AI Officer they appointed in October, whether core organic growth holds at 5%, Altera's runoff, and how much of that $673M pipeline closes in Q4. $CSU.TO #ConstellationSoftware
17/17View on X

$CSU Constellation Software just reported Q3, and it's a better quarter than the headline makes it look.

Top replies from readers

$CSU Constellation Software just reported Q3, and it's a better quarter than the headline makes it look.

Top replies from readers